Phosphodiesterase type 5 inhibitors enhance chemotherapy in preclinical models of esophageal adenocarcinoma by targeting cancer-associated fibroblasts

by Bates, D.O, Breininger, S.P, Clarke, P.A, Collier, P., Cowie, A., Garbis, S.D, Gibson, J., Grabowska, A.M, Harrington, J., Hayden, A., Izadi, F., Jaynes, E., Kyle, E., Manousopoulou, A., Mongan, N.P, Parsons, S.L, Pickering, O., Ritchie, A.A, Rose-Zerilli, M., Saunders, J.H, Sharpe, B.P, Underwood, T.J, Walker, R.C, Walters, Z., Yacqub-Usman, K.
Published 2022